Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Pitavastatin · 1 trial · 2 indications
Pulse wave velocity (PWV)
| Arm | Type | Description |
|---|---|---|
| Pitavastatin | ACTIVE_COMPARATOR | Study Drug |
| Placebo | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| Pitavastatin | DRUG | Statin |
| Placebo | DRUG | Placebo |
Inclusion Criteria: * Boys and girls aged 10 to 19 years (with 2-year availability for study participation) * BMI ≥85th percentile (using Centers for Disease Control (CDC) BMI charts) * Fasting lipid profile x2 each with all of the following: * LDL-C \<160 mg/dL and ≥90 mg/dL, and * TG (trigly...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 2 | PHASE3 | Lepodisiran |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Enlicitide, Rosuvastatin |
| NewAmsterdam Pharma Company N.V. | NAMS | 3 | PHASE3 | obicetrapib, ezetimibe daily |
| AstraZeneca PLC | AZN | 3 | PHASE2 | AZD0780, Rosuvastatin |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE1 | ARO-DIMERPA |
| Novartis AG Sponsored ADR | NVS | 1 | - | Undisclosed |
| CRISPR Therapeutics AG | CRSP | 1 | PHASE1 | CTX310 |
| HeartFlow, Inc. | HTFL | 1 | N/A | Rosuvastatin |
Pitavastatin is a small molecule drug being studied for the treatment of dyslipidemia, a condition characterized by abnormal levels of lipids in the blood. It is being investigated in the context of obesity-related dyslipidemia in adolescents. The drug is currently in Phase 3 clinical development.
Pitavastatin is being developed by Elevance Health, Inc., a company traded on the stock exchange under the ticker symbol ELV. The company is conducting clinical research to evaluate the drug's safety and efficacy in patients with dyslipidemia.
Pitavastatin is in Phase 3 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The Phase 3 trial has been completed, and the drug is being evaluated for its potential to treat dyslipidemia.
Pitavastatin has been studied in a Phase 3 clinical trial with the identifier NCT02956590, titled "Dyslipidemia of Obesity Intervention in Teens." This randomized, double-blind, placebo-controlled trial enrolled 122 participants aged 10 years and older with dyslipidemia and obesity. The trial was conducted in the United States and Canada and has been completed.
Pitavastatin is a small molecule drug. Its mechanism of action involves targeting lipid metabolism to reduce abnormal levels of lipids in the blood. It is being studied for its ability to improve lipid profiles in patients with dyslipidemia, particularly in the context of obesity.
Pitavastatin is not FDA approved for the indication being studied. It is an investigational drug currently in Phase 3 clinical development. The completed clinical trial has provided data, but the drug has not yet received regulatory approval for the treatment of dyslipidemia.